Thalidomide
Mostrando 1-12 de 91 artigos, teses e dissertações.
-
1. Chronic recalcitrant erythema nodosum leprosum: therapeutic dilemma and role of mycobacterium indicus pranii vaccine
Abstract Erythema nodosum leprosum is a severe immune reaction that complicates the usual course of multibacillary leprosy. There is increased activation of T-cells in erythema nodosum leprosum. Treatment modalities available to date for the management are systemic steroids, thalidomide, methotrexate, cyclophosphamide, azathioprine, minocycline, and apremila
Anais Brasileiros de Dermatologia. Publicado em: 2022
-
2. Impact of quality of response on survival outcomes among multiple myeloma patients treated with novel agents – a retrospective analysis
Abstract BACKGROUND: In this era of target therapies, novel data on the correlation between response endpoints and survival outcomes in multiple myeloma have arisen. OBJECTIVE: To determine the impact of quality of response on clinical outcomes, using first-line treatment, and identify risk factors influencing progression-free survival (PFS) and overall su
Sao Paulo Medical Journal. Publicado em: 2022
-
3. Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation
ABSTRACT Background: The treatment of multiple myeloma (MM) has evolved significantly in the past decade, and new drug combinations have improved the response rates and prolonged survival. Studies comparing different induction chemotherapy regimens have shown that triple combinations have better results than double combinations. However, comparisons among d
Hematol., Transfus. Cell Ther.. Publicado em: 2020-06
-
4. Effect of thalidomide on bone marrow angiogenesis in multiple myeloma patients
ABSTRACT Background: Bone marrow angiogenesis is increased in multiple myeloma (MM) patients, prompting the rationale for using antiangiogenic drugs in the treatment of these patients. Objective: To assess angiogenesis in patients with MM at diagnosis and following treatment with an antiangiogenic drug. Patients and Methods: Twenty-three patients with new
Hematol., Transfus. Cell Ther.. Publicado em: 2020-06
-
5. O uso do caso talidomida auxiliando na construção de significados em aulas de Química do Ensino Superior
Studies conducted in the field of education have, in many cases, highlighted the little insertion of teaching and learning theories in Natural Sciences classes, in Higher Education. We developed this study to analyze how Chemistry professors take ownership of a historical case to explain the concepts they develop in their classes. To do so, we analyzed this
Quím. Nova. Publicado em: 2020-04
-
6. Thalidomide Reduces Cell Proliferation in Endometriosis Experimentally Induced in Rats
Resumo Objetivo Analisar o efeito da talidomida na progressão de lesões endometrióticas induzidas experimentalmente em ratas e caracterizar o padrão de proliferação celular pela marcação imunohistoquímica de Antígeno Nuclear de Célula Proliferativa (PCNA) no endométrio eutópico e ectópico. Métodos Quinze ratas Wistar foram submetidas a lap
Rev. Bras. Ginecol. Obstet.. Publicado em: 20/12/2019
-
7. Epidemiological, clinical and immune factors that influence the persistence of antiphospholipid antibodies in leprosy
Abstract Introduction: Antiphospholipid antibodies (aPL) are described in individuals with leprosy without the clinical features of antiphospholipid antibody syndrome (APS), a condition involving thromboembolic phenomena. We have described the persistence of these antibodies for over 5 years in patients with leprosy after specific treatment. Objectives: To
Adv. rheumatol.. Publicado em: 09/12/2019
-
8. Infections in patients with multiple myeloma treated with conventional chemotherapy: a single-center, 10-year experience in Pakistan
ABSTRACT Introduction: Multiple myeloma (MM) is a common hematologic malignancy with variable degrees of immunodeficiency. Disease- and treatment-related compromise of the immune system predisposes patients to infections, which are a major cause of morbidity and mortality. Objective: We aimed to establish the incidence and main characteristics of infection
Hematol., Transfus. Cell Ther.. Publicado em: 25/11/2019
-
9. The tale of lenalidomide clinical superiority over thalidomide and regulatory and cost-effectiveness issues
Resumo A Agência Nacional de Vigilância Sanitária (ANVISA) aprovou em abril de 2017 a lenalidomida (LEN) para o mieloma múltiplo (MM) e síndrome mielodisplásica. A ANVISA havia negado o registro em 2010, e indeferido um recurso apresentado em 2012. O motivo do indeferimento foi a falta de estudos comparativos de efetividade demonstrando que LEN era mai
Ciênc. saúde coletiva. Publicado em: 26/09/2019
-
10. Necrobiotic xanthogranuloma associated with smoldering multiple myeloma: satisfactory response to cyclophosphamide, dexamethasone, and thalidomide
Abstract: Necrobiotic xanthogranuloma is a rare chronic condition, belonging to the group C non-Langerhans cell histiocytoses, which is relevant due to the possibility of extracutaneous involvement and association with systemic diseases, particularly hematologic malignancies. The case reported here was only diagnosed after nine years of evolution and was ass
An. Bras. Dermatol.. Publicado em: 29/07/2019
-
11. Adverse events in patients with leprosy on treatment with thalidomide
Abstract INTRODUCTION: Thalidomide, used to treat erythema nodosum leprosum (ENL), is associated with severe adverse events (AEs) and is highly teratogenic. METHODS: A cross-sectional study was conducted on thalidomide-treated patients with ENL. AEs and selected variables were investigated through interviews and assessment of medical records. Odds ratios
Rev. Soc. Bras. Med. Trop.. Publicado em: 11/04/2019
-
12. Low density lipoprotein modified silica nanoparticles loaded with docetaxel and thalidomide for effective chemotherapy of liver cancer
In the present study, we successfully developed a docetaxel (DTX) and thalidomide (TDD) co-delivery system based on low density lipoprotein (LDL) modified silica nanoparticles (LDL/SLN/DTX/TDD). By employing the tumor homing property of LDL and the drug-loading capability of silica nanoparticles, the prepared LDL/SLN/DTX/TDD was expected to locate and specif
Braz J Med Biol Res. Publicado em: 01/03/2018